[
  {
    "ts": null,
    "headline": "NVIDIA Announces Financial Results for Fourth Quarter and Fiscal 2026",
    "summary": "NVIDIA corporate headquarters NVIDIA corporate headquarters in Silicon Valley Record quarterly revenue of $68.1 billion, up 20% from Q3 and up 73% from a year agoRecord quarterly Data Center revenue of $62.3 billion, up 22% from Q3 and up 75% from a year agoRecord full-year revenue of $215.9 billion, up 65% SANTA CLARA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NVIDIA (NASDAQ: NVDA) today reported record revenue for the fourth quarter ended January 25, 2026, of $68.1 billion, up 20% from the pre",
    "url": "https://finnhub.io/api/news?id=b45b1b4d535d6906eefd3bc224b240c55b8f32695b25499eb9cf69348e89ae0a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772055060,
      "headline": "NVIDIA Announces Financial Results for Fourth Quarter and Fiscal 2026",
      "id": 139225019,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVIDIA corporate headquarters NVIDIA corporate headquarters in Silicon Valley Record quarterly revenue of $68.1 billion, up 20% from Q3 and up 73% from a year agoRecord quarterly Data Center revenue of $62.3 billion, up 22% from Q3 and up 75% from a year agoRecord full-year revenue of $215.9 billion, up 65% SANTA CLARA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NVIDIA (NASDAQ: NVDA) today reported record revenue for the fourth quarter ended January 25, 2026, of $68.1 billion, up 20% from the pre",
      "url": "https://finnhub.io/api/news?id=b45b1b4d535d6906eefd3bc224b240c55b8f32695b25499eb9cf69348e89ae0a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly acquires Orna Therapeutics for $2.4B to disrupt CAR-T market",
    "summary": "CAR-T therapies have changed the oncology space, but their cost and complexity have confined these treatments to specialized cancer centers, with price tags of up to $400,000 per treatment. For the millions of US patients with B-cell–driven autoimmune diseases like lupus, that model is not ...",
    "url": "https://finnhub.io/api/news?id=fd4e796132529aa6012d7e79182eecaeddaced809c77c17e0761d9715935e3ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772050380,
      "headline": "Eli Lilly acquires Orna Therapeutics for $2.4B to disrupt CAR-T market",
      "id": 139225081,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "CAR-T therapies have changed the oncology space, but their cost and complexity have confined these treatments to specialized cancer centers, with price tags of up to $400,000 per treatment. For the millions of US patients with B-cell–driven autoimmune diseases like lupus, that model is not ...",
      "url": "https://finnhub.io/api/news?id=fd4e796132529aa6012d7e79182eecaeddaced809c77c17e0761d9715935e3ea"
    }
  },
  {
    "ts": null,
    "headline": "RBC Capital Initiates Coverage of Eli Lilly and (LLY) with Outperform Recommendation",
    "summary": "RBC Capital Initiates Coverage of Eli Lilly and (LLY) with Outperform Recommendation",
    "url": "https://finnhub.io/api/news?id=e0666d03289ef6df855f2f38060afd9f3151c811cfb36afdc97a997f577081df",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772049820,
      "headline": "RBC Capital Initiates Coverage of Eli Lilly and (LLY) with Outperform Recommendation",
      "id": 139224410,
      "image": "",
      "related": "LLY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e0666d03289ef6df855f2f38060afd9f3151c811cfb36afdc97a997f577081df"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know.",
    "summary": "Eli Lilly has seen revenue and earnings soar in recent years.",
    "url": "https://finnhub.io/api/news?id=024be9fbe1a12392db0933ead67f56dd7d268c97dc94ae3de29500d2532bb1b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772048100,
      "headline": "Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know.",
      "id": 139223906,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly has seen revenue and earnings soar in recent years.",
      "url": "https://finnhub.io/api/news?id=024be9fbe1a12392db0933ead67f56dd7d268c97dc94ae3de29500d2532bb1b4"
    }
  },
  {
    "ts": null,
    "headline": "1 Reason Why I'd Hold This Weight‑Loss Drug Leader Through Any Market Crash",
    "summary": "Although pegged as a weight-loss stock, this drug maker's core business has long been diabetes.",
    "url": "https://finnhub.io/api/news?id=3efa5c7d65988f06bb2cfd979ca0602c0069f3e42d69c53b9e72ee3d80348423",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772043600,
      "headline": "1 Reason Why I'd Hold This Weight‑Loss Drug Leader Through Any Market Crash",
      "id": 139223907,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Although pegged as a weight-loss stock, this drug maker's core business has long been diabetes.",
      "url": "https://finnhub.io/api/news?id=3efa5c7d65988f06bb2cfd979ca0602c0069f3e42d69c53b9e72ee3d80348423"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Releases Positive Results From Phase 3 VIVID-2 Open-Label Extension Study",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Buy and Hold For the Next 3 Years. On February 19, Eli Lilly and Company (NYSE:LLY) released positive results from the Phase 3 VIVID-2 open-label extension study. The study is testing Omvoh (mirikizumab-mrkz) to treat Crohn’s disease and ulcerative colitis. ​The study found […]",
    "url": "https://finnhub.io/api/news?id=fc21074cc95a63eebf407a3c5a6bd5dea233756cfef991543d926e6538cb6149",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772035810,
      "headline": "Eli Lilly (LLY) Releases Positive Results From Phase 3 VIVID-2 Open-Label Extension Study",
      "id": 139215420,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Buy and Hold For the Next 3 Years. On February 19, Eli Lilly and Company (NYSE:LLY) released positive results from the Phase 3 VIVID-2 open-label extension study. The study is testing Omvoh (mirikizumab-mrkz) to treat Crohn’s disease and ulcerative colitis. ​The study found […]",
      "url": "https://finnhub.io/api/news?id=fc21074cc95a63eebf407a3c5a6bd5dea233756cfef991543d926e6538cb6149"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Seen Resilient as BofA Downplays Novo Nordisk GLP-1 Price Impact",
    "summary": "Eli Lilly and Company (NYSE:LLY) is included among the Goldman Sachs Dividend Stocks: Top 14 Stock Picks. On February 24, BofA said Novo Nordisk’s decision to cut GLP-1 list prices may draw attention, but the firm does not expect a meaningful impact on the US market. BofA views the move mainly as an effort to […]",
    "url": "https://finnhub.io/api/news?id=61472bd9913e9091c8fa35293728586d01b9820549a34ef5b387844abc4be375",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772034933,
      "headline": "Eli Lilly (LLY) Seen Resilient as BofA Downplays Novo Nordisk GLP-1 Price Impact",
      "id": 139210535,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is included among the Goldman Sachs Dividend Stocks: Top 14 Stock Picks. On February 24, BofA said Novo Nordisk’s decision to cut GLP-1 list prices may draw attention, but the firm does not expect a meaningful impact on the US market. BofA views the move mainly as an effort to […]",
      "url": "https://finnhub.io/api/news?id=61472bd9913e9091c8fa35293728586d01b9820549a34ef5b387844abc4be375"
    }
  },
  {
    "ts": null,
    "headline": "BofA sees limited impact to Eli Lilly’s franchise from Novo’s GLP-1 price update",
    "summary": "BofA says that today’s announcement that Novo Nordisk (NVO) plans to slash GLP-1 list prices offers a flashy headline, but in the firm’s view the update is unlikely to have any material impact on the U.S. market. BofA sees today’s move as an attempt to reduce copay/coinsurance costs to patients in settings where that figure is calculated of list/WAC price. More broadly, the firm thinks it’s fair for investors to wonder if/when commercial reimbursement of GLP-1’s could become more commonplace, wi",
    "url": "https://finnhub.io/api/news?id=d54c8ea45be490335ee89bc413ce89037f989b15d7f6b0f66ffe698822962853",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772034061,
      "headline": "BofA sees limited impact to Eli Lilly’s franchise from Novo’s GLP-1 price update",
      "id": 139210536,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "BofA says that today’s announcement that Novo Nordisk (NVO) plans to slash GLP-1 list prices offers a flashy headline, but in the firm’s view the update is unlikely to have any material impact on the U.S. market. BofA sees today’s move as an attempt to reduce copay/coinsurance costs to patients in settings where that figure is calculated of list/WAC price. More broadly, the firm thinks it’s fair for investors to wonder if/when commercial reimbursement of GLP-1’s could become more commonplace, wi",
      "url": "https://finnhub.io/api/news?id=d54c8ea45be490335ee89bc413ce89037f989b15d7f6b0f66ffe698822962853"
    }
  },
  {
    "ts": null,
    "headline": "Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie",
    "summary": "Investing.com -- RBC analysts say U.S. large cap pharma offers defensive exposure and earnings upside as artificial intelligence reshapes drug development.",
    "url": "https://finnhub.io/api/news?id=fd179c9bbe20abdd9972864ad70fb56fd3bd3c1f562aeee5619e9286e4076039",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772031440,
      "headline": "Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie",
      "id": 139210537,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- RBC analysts say U.S. large cap pharma offers defensive exposure and earnings upside as artificial intelligence reshapes drug development.",
      "url": "https://finnhub.io/api/news?id=fd179c9bbe20abdd9972864ad70fb56fd3bd3c1f562aeee5619e9286e4076039"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finnhub.io/api/news?id=f7a093eaa5218f6357a1d47783ed661f14ebbdede68a3e43866c5c36a9715229",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772030703,
      "headline": "Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term",
      "id": 139215421,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
      "url": "https://finnhub.io/api/news?id=f7a093eaa5218f6357a1d47783ed661f14ebbdede68a3e43866c5c36a9715229"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's GLP-1 Blockbusters Drive 2025 Revenue Surge: What's Ahead?",
    "summary": "LLY's Mounjaro and Zepbound drove 56% of revenues in 2025 as obesity demand surged, with new launches and Medicare access set to fuel growth.",
    "url": "https://finnhub.io/api/news?id=f1e974b0b9c2eaf55ad5bd637bcbf4247cc6946af5a9b2b7eebf8ad133b99db7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772026800,
      "headline": "Lilly's GLP-1 Blockbusters Drive 2025 Revenue Surge: What's Ahead?",
      "id": 139210538,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY's Mounjaro and Zepbound drove 56% of revenues in 2025 as obesity demand surged, with new launches and Medicare access set to fuel growth.",
      "url": "https://finnhub.io/api/news?id=f1e974b0b9c2eaf55ad5bd637bcbf4247cc6946af5a9b2b7eebf8ad133b99db7"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk's Loss Is Eli Lilly's Gain",
    "summary": "Eli Lilly and Company (NYSE:LLY) shares are up on Monday as the company benefits from positive market sentiment following Novo Nordisk A/S’ (NYSE:NVO) disappointing trial results for a weight-loss drug, adding pressure as broader markets edged lower. Eli Lilly Gains as Novo Nordisk Trial Setback Novo Nordisk’s stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly’s tirzepatide, marketed under the Zepbound and Mounjaro brands",
    "url": "https://finnhub.io/api/news?id=d6b28c212d643327f17dfb4f44372ca2b5da2a99a37ef14b9393815929d1ef90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772024463,
      "headline": "Novo Nordisk's Loss Is Eli Lilly's Gain",
      "id": 139207511,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) shares are up on Monday as the company benefits from positive market sentiment following Novo Nordisk A/S’ (NYSE:NVO) disappointing trial results for a weight-loss drug, adding pressure as broader markets edged lower. Eli Lilly Gains as Novo Nordisk Trial Setback Novo Nordisk’s stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly’s tirzepatide, marketed under the Zepbound and Mounjaro brands",
      "url": "https://finnhub.io/api/news?id=d6b28c212d643327f17dfb4f44372ca2b5da2a99a37ef14b9393815929d1ef90"
    }
  },
  {
    "ts": null,
    "headline": "Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and More",
    "summary": "Pre-Market Stock Futures: Futures are trading higher this morning, but what a difference a day makes after a “Meltdown Monday.” Stocks rallied on Tuesday, and all major indices closed higher. While not recouping all of the losses from Monday, a strong bounce-back was a welcome sight for investors. A combination of a rebound in technology ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and More",
    "url": "https://finnhub.io/api/news?id=6c5bc0e42222b3af06e96f91099f1353654595b3252e49495b59ae2201cfc060",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772024267,
      "headline": "Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and More",
      "id": 139207793,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pre-Market Stock Futures: Futures are trading higher this morning, but what a difference a day makes after a “Meltdown Monday.” Stocks rallied on Tuesday, and all major indices closed higher. While not recouping all of the losses from Monday, a strong bounce-back was a welcome sight for investors. A combination of a rebound in technology ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and More",
      "url": "https://finnhub.io/api/news?id=6c5bc0e42222b3af06e96f91099f1353654595b3252e49495b59ae2201cfc060"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low",
    "summary": "After finding itself some unwanted attention this week, Novo Nordisk (NYSE:NVO) has dropped 22% in the past week and 56% over the past year, now sitting near its 52-week low. As a result, Reddit sentiment has followed along with this downward shift, sliding from a quarterly average of 56 to a weekly average of 43 ... Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low",
    "url": "https://finnhub.io/api/news?id=3108dcba9af60d0dcda0ee073445818489686ec3fd29ca707c0e6ac26e6e1382",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772021335,
      "headline": "Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low",
      "id": 139207512,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "After finding itself some unwanted attention this week, Novo Nordisk (NYSE:NVO) has dropped 22% in the past week and 56% over the past year, now sitting near its 52-week low. As a result, Reddit sentiment has followed along with this downward shift, sliding from a quarterly average of 56 to a weekly average of 43 ... Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low",
      "url": "https://finnhub.io/api/news?id=3108dcba9af60d0dcda0ee073445818489686ec3fd29ca707c0e6ac26e6e1382"
    }
  },
  {
    "ts": null,
    "headline": "Columbia Balanced Fund Q4 2025 Contributors And Detractors",
    "summary": "Columbia Balanced Fund Q4 2025 Contributors And Detractors",
    "url": "https://finnhub.io/api/news?id=b0f5da22be3c117ebd24c4fb6f374b67e7521ebf9a1c6a9f50ed75e8cb598103",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772018580,
      "headline": "Columbia Balanced Fund Q4 2025 Contributors And Detractors",
      "id": 139211095,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b0f5da22be3c117ebd24c4fb6f374b67e7521ebf9a1c6a9f50ed75e8cb598103"
    }
  },
  {
    "ts": null,
    "headline": "Ozempic Price War - Novo Nordisk Slashes Prices By 50%",
    "summary": "Novo Nordisk plans up to 50% U.S. price cuts on Wegovy, Ozempic, and Rybelsus by 2027, sending shares lower in premarket trade.",
    "url": "https://finnhub.io/api/news?id=886a7198ca5e2368188783f77b0a6da319e6acc23fcf52cf7248a12d2501479f",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772014435,
      "headline": "Ozempic Price War - Novo Nordisk Slashes Prices By 50%",
      "id": 139208166,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/25/Valparaiso--In-Usa-December-13--2023-Oze.jpeg?width=2048&height=1536",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "Novo Nordisk plans up to 50% U.S. price cuts on Wegovy, Ozempic, and Rybelsus by 2027, sending shares lower in premarket trade.",
      "url": "https://finnhub.io/api/news?id=886a7198ca5e2368188783f77b0a6da319e6acc23fcf52cf7248a12d2501479f"
    }
  },
  {
    "ts": null,
    "headline": "Oruka Therapeutics: A Potential Future Psoriasis Play",
    "summary": "Oruka Therapeutics: A Potential Future Psoriasis Play",
    "url": "https://finnhub.io/api/news?id=20fd663d56461d661f04230d74318f359bae608478fd3016a1ee3b0648a05e09",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772013790,
      "headline": "Oruka Therapeutics: A Potential Future Psoriasis Play",
      "id": 139209740,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=20fd663d56461d661f04230d74318f359bae608478fd3016a1ee3b0648a05e09"
    }
  },
  {
    "ts": null,
    "headline": "These 4 charts show the scale of Novo Nordisk's woes",
    "summary": "Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.",
    "url": "https://finnhub.io/api/news?id=16985f75739012f9804d2c8eecc059bddaf431662a1b6197fe1e120314a3474f",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771997562,
      "headline": "These 4 charts show the scale of Novo Nordisk's woes",
      "id": 139212445,
      "image": "https://image.cnbcfm.com/api/v1/image/108245068-1766477256303-gettyimages-2228673815-raa-novonord250809_npj4Z.jpeg?v=1768247892&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.",
      "url": "https://finnhub.io/api/news?id=16985f75739012f9804d2c8eecc059bddaf431662a1b6197fe1e120314a3474f"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk To Slash GLP-1 Drug Prices By Up To 50% In US Starting 2027",
    "summary": "Novo Nordisk (NYSE: NVO) announced plans to cut the list prices of these drugs by up to 50% in the U.S. starting in 2027, on Tuesday.",
    "url": "https://finnhub.io/api/news?id=20572be0f30b15895711dad6105a0abf3beaa9ee49e9448402c71e82be0e4e97",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771996441,
      "headline": "Novo Nordisk To Slash GLP-1 Drug Prices By Up To 50% In US Starting 2027",
      "id": 139208168,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/25/Valparaiso-In-Usa---March-21--2024-Ozemp.jpeg?width=2048&height=1536",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "Novo Nordisk (NYSE: NVO) announced plans to cut the list prices of these drugs by up to 50% in the U.S. starting in 2027, on Tuesday. ",
      "url": "https://finnhub.io/api/news?id=20572be0f30b15895711dad6105a0abf3beaa9ee49e9448402c71e82be0e4e97"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly Stock Slumped Today",
    "summary": "Investors worried that the company could take quite a revenue hit due to a competitor's move.",
    "url": "https://finnhub.io/api/news?id=435e5fc6e895bdd9be17462b2571f80ba3bbe4eaf2c8f414d28597d3a95ecec8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771982125,
      "headline": "Why Eli Lilly Stock Slumped Today",
      "id": 139203102,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investors worried that the company could take quite a revenue hit due to a competitor's move.",
      "url": "https://finnhub.io/api/news?id=435e5fc6e895bdd9be17462b2571f80ba3bbe4eaf2c8f414d28597d3a95ecec8"
    }
  }
]